ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation

for the ClinGen RASopathy Working Group

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Purpose: Standardized and accurate variant assessment is essential for effective medical care. To that end, Clinical Genome (ClinGen) Resource clinical domain working groups (CDWGs) are systematically reviewing disease-associated genes for sufficient evidence to support disease causality and creating disease-specific specifications of American College of Medical Genetics and Genomics–Association for Molecular Pathology (ACMG-AMP) guidelines for consistent and accurate variant classification. Methods: The ClinGen RASopathy CDWG established an expert panel to curate gene information and generate gene- and disease-specific specifications to ACMG-AMP variant classification framework. These specifications were tested by classifying 37 exemplar pathogenic variants plus an additional 66 variants in ClinVar distributed across nine RASopathy genes. Results: RASopathy-related specifications were applied to 16 ACMG-AMP criteria, with 5 also having adjustable strength with availability of additional evidence. Another 5 criteria were deemed not applicable. Key adjustments to minor allele frequency thresholds, multiple de novo occurrence events and/or segregation, and strength adjustments impacted 60% of variant classifications. Unpublished case-level data from participating laboratories impacted 45% of classifications supporting the need for data sharing. Conclusion: RAS-specific ACMG-AMP specifications optimized the utility of available clinical evidence and Ras/MAPK pathway–specific characteristics to consistently classify RASopathy-associated variants. These specifications highlight how grouping genes by shared features promotes rapid multigenic variant assessment without sacrificing specificity and accuracy.

Original languageEnglish (US)
Pages (from-to)1334-1345
Number of pages12
JournalGenetics in Medicine
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Molecular Pathology
Medical Genetics
Genes
Genome
Information Dissemination
Gene Frequency
Causality
Guidelines

Keywords

  • ClinGen
  • Noonan
  • Ras/MAPK
  • RASopathy
  • variant interpretation

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. / for the ClinGen RASopathy Working Group.

In: Genetics in Medicine, Vol. 20, No. 11, 01.11.2018, p. 1334-1345.

Research output: Contribution to journalArticle

for the ClinGen RASopathy Working Group. / ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation. In: Genetics in Medicine. 2018 ; Vol. 20, No. 11. pp. 1334-1345.
@article{eb9aaa0d01694b129e2024dc8cf4cd9e,
title = "ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation",
abstract = "Purpose: Standardized and accurate variant assessment is essential for effective medical care. To that end, Clinical Genome (ClinGen) Resource clinical domain working groups (CDWGs) are systematically reviewing disease-associated genes for sufficient evidence to support disease causality and creating disease-specific specifications of American College of Medical Genetics and Genomics–Association for Molecular Pathology (ACMG-AMP) guidelines for consistent and accurate variant classification. Methods: The ClinGen RASopathy CDWG established an expert panel to curate gene information and generate gene- and disease-specific specifications to ACMG-AMP variant classification framework. These specifications were tested by classifying 37 exemplar pathogenic variants plus an additional 66 variants in ClinVar distributed across nine RASopathy genes. Results: RASopathy-related specifications were applied to 16 ACMG-AMP criteria, with 5 also having adjustable strength with availability of additional evidence. Another 5 criteria were deemed not applicable. Key adjustments to minor allele frequency thresholds, multiple de novo occurrence events and/or segregation, and strength adjustments impacted 60{\%} of variant classifications. Unpublished case-level data from participating laboratories impacted 45{\%} of classifications supporting the need for data sharing. Conclusion: RAS-specific ACMG-AMP specifications optimized the utility of available clinical evidence and Ras/MAPK pathway–specific characteristics to consistently classify RASopathy-associated variants. These specifications highlight how grouping genes by shared features promotes rapid multigenic variant assessment without sacrificing specificity and accuracy.",
keywords = "ClinGen, Noonan, Ras/MAPK, RASopathy, variant interpretation",
author = "{for the ClinGen RASopathy Working Group} and Gelb, {Bruce D.} and H{\'e}l{\`e}ne Cav{\'e} and Dillon, {Mitchell W.} and Gripp, {Karen W.} and Lee, {Jennifer A.} and Heather Mason-Suares and Rauen, {Katherine A} and Bradley Williams and Martin Zenker and Vincent, {Lisa M.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/gim.2018.3",
language = "English (US)",
volume = "20",
pages = "1334--1345",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - ClinGen’s RASopathy Expert Panel consensus methods for variant interpretation

AU - for the ClinGen RASopathy Working Group

AU - Gelb, Bruce D.

AU - Cavé, Hélène

AU - Dillon, Mitchell W.

AU - Gripp, Karen W.

AU - Lee, Jennifer A.

AU - Mason-Suares, Heather

AU - Rauen, Katherine A

AU - Williams, Bradley

AU - Zenker, Martin

AU - Vincent, Lisa M.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: Standardized and accurate variant assessment is essential for effective medical care. To that end, Clinical Genome (ClinGen) Resource clinical domain working groups (CDWGs) are systematically reviewing disease-associated genes for sufficient evidence to support disease causality and creating disease-specific specifications of American College of Medical Genetics and Genomics–Association for Molecular Pathology (ACMG-AMP) guidelines for consistent and accurate variant classification. Methods: The ClinGen RASopathy CDWG established an expert panel to curate gene information and generate gene- and disease-specific specifications to ACMG-AMP variant classification framework. These specifications were tested by classifying 37 exemplar pathogenic variants plus an additional 66 variants in ClinVar distributed across nine RASopathy genes. Results: RASopathy-related specifications were applied to 16 ACMG-AMP criteria, with 5 also having adjustable strength with availability of additional evidence. Another 5 criteria were deemed not applicable. Key adjustments to minor allele frequency thresholds, multiple de novo occurrence events and/or segregation, and strength adjustments impacted 60% of variant classifications. Unpublished case-level data from participating laboratories impacted 45% of classifications supporting the need for data sharing. Conclusion: RAS-specific ACMG-AMP specifications optimized the utility of available clinical evidence and Ras/MAPK pathway–specific characteristics to consistently classify RASopathy-associated variants. These specifications highlight how grouping genes by shared features promotes rapid multigenic variant assessment without sacrificing specificity and accuracy.

AB - Purpose: Standardized and accurate variant assessment is essential for effective medical care. To that end, Clinical Genome (ClinGen) Resource clinical domain working groups (CDWGs) are systematically reviewing disease-associated genes for sufficient evidence to support disease causality and creating disease-specific specifications of American College of Medical Genetics and Genomics–Association for Molecular Pathology (ACMG-AMP) guidelines for consistent and accurate variant classification. Methods: The ClinGen RASopathy CDWG established an expert panel to curate gene information and generate gene- and disease-specific specifications to ACMG-AMP variant classification framework. These specifications were tested by classifying 37 exemplar pathogenic variants plus an additional 66 variants in ClinVar distributed across nine RASopathy genes. Results: RASopathy-related specifications were applied to 16 ACMG-AMP criteria, with 5 also having adjustable strength with availability of additional evidence. Another 5 criteria were deemed not applicable. Key adjustments to minor allele frequency thresholds, multiple de novo occurrence events and/or segregation, and strength adjustments impacted 60% of variant classifications. Unpublished case-level data from participating laboratories impacted 45% of classifications supporting the need for data sharing. Conclusion: RAS-specific ACMG-AMP specifications optimized the utility of available clinical evidence and Ras/MAPK pathway–specific characteristics to consistently classify RASopathy-associated variants. These specifications highlight how grouping genes by shared features promotes rapid multigenic variant assessment without sacrificing specificity and accuracy.

KW - ClinGen

KW - Noonan

KW - Ras/MAPK

KW - RASopathy

KW - variant interpretation

UR - http://www.scopus.com/inward/record.url?scp=85054690075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054690075&partnerID=8YFLogxK

U2 - 10.1038/gim.2018.3

DO - 10.1038/gim.2018.3

M3 - Article

C2 - 29493581

AN - SCOPUS:85054690075

VL - 20

SP - 1334

EP - 1345

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 11

ER -